BMC Bioinformatics · 2019 · 69 citations · 28 references
ComputingData SciencePharmacologyData MiningDrug DiscoveryMachine LearningComputational Drug DiscoveryKernel MethodsSupport Vector MachinesComputational Prediction ModelsDrug - Drug Interaction DetectionK-nearest NeighborsOne-class Support Vector MachinesPositive-unlabeled LearningPredictionSimilarity-based LearningUnlabeled Learning
BACKGROUND: Drug-drug interactions (DDIs) are a major concern in patients' medication. It's unfeasible to identify all potential DDIs using experimental methods which are time-consuming and expensive. Computational methods provide an effective strategy, however, facing challenges due to the lack of experimentally verified negative samples. RESULTS: To address this problem, we propose a novel positive-unlabeled learning method named DDI-PULearn for large-scale drug-drug-interaction predictions. DDI-PULearn first generates seeds of reliable negatives via OCSVM (one-class support vector machine) under a high-recall constraint and via the cosine-similarity based KNN (k-nearest neighbors) as well. Then trained with all the labeled positives (i.e., the validated DDIs) and the generated seed negatives, DDI-PULearn employs an iterative SVM to identify a set of entire reliable negatives from the unlabeled samples (i.e., the unobserved DDIs). Following that, DDI-PULearn represents all the labeled positives and the identified negatives as vectors of abundant drug properties by a similarity-based method. Finally, DDI-PULearn transforms these vectors into a lower-dimensional space via PCA (principal component analysis) and utilizes the compressed vectors as input for binary classifications. The performance of DDI-PULearn is evaluated on simulative prediction for 149,878 possible interactions between 548 drugs, comparing with two baseline methods and five state-of-the-art methods. Related experiment results show that the proposed method for the representation of DDIs characterizes them accurately. DDI-PULearn achieves superior performance owing to the identified reliable negatives, outperforming all other methods significantly. In addition, the predicted novel DDIs suggest that DDI-PULearn is capable to identify novel DDIs. CONCLUSIONS: The results demonstrate that positive-unlabeled learning paves a new way to tackle the problem caused by the lack of experimentally verified negatives in the computational prediction of DDIs.
28
DrugBank 5.0: a major update to the DrugBank database for 2018
David S. Wishart, Yannick Djoumbou-Feunang, An Chi Guo et al. · Nucleic Acids Research · 2017 · 8.8K citations · Full text
PubChem 2019 update: improved access to chemical data
Sunghwan Kim, Jie Chen, Tiejun Cheng et al. · Nucleic Acids Research · 2018 · 3.4K citations · Full text
The SIDER database of drugs and side effects
Michael Kuhn, Ivica Letunić, Lars Juhl Jensen et al. · Nucleic Acids Research · 2015 · 1.5K citations · Full text
Data-Driven Prediction of Drug Effects and Interactions
Nicholas P. Tatonetti, Patrick P. Ye, Roxana Daneshjou et al. · Science Translational Medicine · 2012 · 929 citations
The Comparative Toxicogenomics Database: update 2017
Allan Peter Davis, Cynthia Grondin, Robin J. Johnson et al. · Nucleic Acids Research · 2016 · 565 citations · Full text